Romosozumab in Postmenopausal Women with Osteopenia
Authors:
- Michael R McClungMMMichael R McClung
- Andreas GrauerAGAndreas Grauer
- 24 April 2014
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 370 (17) , 1664-1665
Abstract
McClung and colleagues (Jan. 30 issue)1 report increases in bone mineral density in postmenopausal women after treatment with romosozumab, a humanized monoclonal anti-sclerostin antibody. The incidence of severe adverse events in the placebo group was 14%, as compared with 10% in the group receiving the highest dose of romosozumab. The authors point out that the risk of extraskeletal effects with the use of romosozumab is low, since the expression of the gene encoding sclerostin (SOST) “is limited to skeletal tissue.” We dissent from this bone-focused view, since Wnt signaling is increasingly recognized to be involved in vascular pathophysiology.2 Both experimental3 and clinical4 data confirm the expression of SOST protein in calcifying vascular tissues. We acknowledge that it remains to be shown whether sclerostin in the vasculature exerts paracrine antimineralization effects similar to those observed in bone. Recent clinical data showing an inverse association between circulating sclerostin levels and mortality among patients undergoing dialysis further fuel concerns with regard to the cardiovascular safety of drugs targeting sclerostin.5 We therefore consider it mandatory to carefully evaluate the effect of prolonged romosozumab treatment on cardiovascular health, especially in high-risk populations.Keywords
This publication has 9 references indexed in Scilit:
- Romosozumab in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2014
- Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional studyBMC Nephrology, 2013
- The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal womenBone, 2013
- Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?Nephrology Dialysis Transplantation, 2013
- Van Buchem disease: Clinical, biochemical, and densitometric features of patients and disease carriersJournal of Bone and Mineral Research, 2012
- The Regulation of Valvular and Vascular Sclerosis by Osteogenic MorphogensCirculation Research, 2011
- Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnoverJournal of Bone and Mineral Research, 2011
- The Appearance and Modulation of Osteocyte Marker Expression during Calcification of Vascular Smooth Muscle CellsPLOS ONE, 2011
- Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone StrengthJournal of Bone and Mineral Research, 2008